跳至主要内容
临床试验/NCT05573776
NCT05573776已完成不适用

A Pilot Study of the Effect of High Protein Supplement and Exercise Therapy on Preservation of Skeletal Muscle Mass and Quality of Life in Patients With Gastric Cancer and Pancreatic Cancer Treated With Chemotherapy

Yonsei University2 个研究点 分布在 2 个国家目标入组 80 人开始时间: 2020年8月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
80
试验地点
2
主要终点
Comparison of muscle variation between exercise therapy alone and high protein supplement combination groups

研究概览

简要总结

For gastric and pancreatic cancer patients scheduled for primary chemotherapy, we would like to report muscle mass preservation and improvement in quality of life in Chinese characters that received only exercise therapy and high protein supplements at the same time

详细描述

Sixty patients with gastric and pancreatic cancer will be eligible, and 30 patients will be randomly assigned to the exercise therapy + high protein supplement group and 30 patients to the exercise therapy + placebo supplement group.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
19 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Has provided signed written informed Consent
  • Has a histologically confirmed gastric or pancreatic cancer
  • Has a patient scheduled for chemotherapy - Patients who are scheduled to be treated with TS-1 or Xelox for gastric cancer-adjuvant chemotherapy - Patients scheduled for primary chemotherapy for pancreatic cancer-progressive/transitional diseases

排除标准

  • Age under 19 or over 90 year of age
  • Eastern Cooperative Oncology Group (ECOG) ≥ 2
  • Patients with severe malnutritional evaluation (PG-SGAC)
  • Any of the following within 3 months prior to study recruitment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, NYHA class III or IV congestive heart failure, stroke or transient ischemic attack.
  • A person with previous uncontrolled seizures, central nervous system or psychological disorders
  • Have uncontrolled active infection or sepsis
  • Have deep vein thrombosis occurs within 4 weeks prior to the start of test recruitment
  • Severe acute or chronic conditions that may reduce the patient's ability to participate in clinical trials or make it difficult to interpret clinical trial results
  • Pregnant or lactating women. Pregnancy test results are positive in childbearing women
  • Gastrointestinal obstruction, malabsorption syndrome, or diseases that significantly affect digestive functions

结局指标

主要结局

Comparison of muscle variation between exercise therapy alone and high protein supplement combination groups

时间窗: 6weeks

Comparison of muscle variation between the exercise therapy single group and the high-protein supplement combination group as assessed by Bioelectrical impedance analsis (BIA) (performed in Week 6)

Comparison of muscle mass between exercise therapy alone and high protein supplement combination groups

时间窗: 6weeks

Comparison of muscle mass between the exercise therapy single group and the high-protein supplement combination group as assessed by Bioelectrical impedance analsis (BIA) (performed in Week 6)

次要结局

  • Exercise Compliance(3years)
  • High Protein/Placebo Supplement rate(3years)
  • Progression-free survival (PFS)(3years)
  • Overall Survival (OS)(3years)
  • Quality of Life (QoL) Evaluation (Korean version EORTC QLQ-C30)(3years)
  • Nutritional status assessment(3years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验